

## CURRICULUM VITAE

➤ **Name:** Eun Joo Kang, M.D., Ph.D.

➤ **PRESENT TITLE AND AFFILIATION**

### Primary Appointment

Assistant Professor, Department of Medical Oncology, Medical School, Korea University  
Korea University Guro Hospital, 148 Gurodong-ro, Guro-Gu, Seoul, Korea (08308)

### CITIZENSHIP

Republic of Korea

➤ **EDUCATION**

### Degree-Granting Education

Korea University Graduate School, Seoul, Korea, Ph.D., 2013 Medical Oncology  
(From Professor Jae Hong Seo, Division of Medical Oncology, Medical School, Korea University, Seoul, Korea)  
Korea University Graduate School, Seoul, Korea, M.S., 2010, Medical Oncology  
(From Professor Jae Hong Seo, Division of Medical Oncology, Medical School, Korea University, Seoul, Korea)  
Korea University Medical College, Seoul, Korea, M.D.& Bachelor, 2006

### Training Experience

Internship and Residency, Korea University Medical Center, 2006-2011

Medical Oncology Fellowship, Seoul National University Hospital, 2011-2012

Medical Oncology Fellowship, Korea University Medical Center, Guro Hospital, 2012-2013

GCP certified, from 2011, every year

➤ **CREDENTIALS**

### Board Certification

#### Licensure(s) Active :

Medical Doctor License Number: 89817

Internal Medicine Specialty License Number: 13071

Medical Oncology/Hematology Sub-specialty License Number:

### Academic Experiences

Clinical Instructor of Medical Oncology, Seoul National University Hospital, 2011-2012

Clinical Instructor of Medical Oncology, Korea University Medical Center, 2012- 2013

Assistant Professor :2014~ now

## Institutional Committee Activities

Lifelong Member, Korea Internal Medicine Association, 2006-Present  
Member, Korea Cancer Association, 2008-Present,  
Member, Korea Association for Clinical Oncology, 2008-Present  
Member, Korea Cancer Study, Group, 2013- Present

### ➤ CLINICAL TRIALS

1. A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE) - **Sub-investigator**
2. A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study] - **Sub-investigator**
3. Randomized, Open, Multi-Center, Phase III Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle **DA-3031**(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy - **Sub-investigator**
4. Neratinib plus paclitaxel plus versus Trastuzumab plus paclitaxel as first line treatment for Erb-2-positive locally recurrent or Metastatic Breast Cancer - **Sub-investigator**
5. A randomized, multicenter, double-blind, placebo-controlled, Phase 3 study of the Bruton's Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma-**Sub-investigator**
6. A Phase III, open-label, randomized study of the combination therapy with NC-6004 and Gemcitabine versus Gemcitabine Alone in Patients with Locally advanced or metastatic pancreatic cancer-**Sub-investigator**
7. A Phase II, Non-comparative, Open label, Multi-center, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen - **Principal investigator**
8. A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung Cancer - **Principal investigator**
9. A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet - **Principal investigator**
10. An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations - **Principal investigator**
11. Randomized phase II study of axitinib in patients with recurrent or metastatic adenoid cystic carcinoma **Principal investigator**